Our Platform

Our platform is designed for tailor-made vaccine candidates. The two primary elements that form our cutting-edge technology are:

• Synthetic Virus-Like Particle (SVLP) that allows an optimal, multivalent and functional presentation of antigen(s). Each particle may present 60-90 copies of the antigenic epitope(s) and includes a modular interchangeable library of structural and functional components. The particle contains a T-helper epitope and a Toll-like receptor (TLR) ligand providing a self-adjuvanted system that drives B and T-cell responses.

• Synthetic Antigen Mimetic (SAM) created using AI, structural biology, crystallography and chemistry. The antigen may be a peptide, glycan or glycopeptide in nature and may represent a B-cell or T-cell epitope. Each antigen is designed to mimic a native epitope with the appropriate structural information. Antigens are identified through data mining, in silico predictions, or knowledge gained from clinical samples such as convalescent sera.